L Klotz

Summary

Affiliation: Sunnybrook and Women's College Health Sciences Centre
Country: Canada

Publications

  1. ncbi request reprint Active surveillance with selective delayed intervention for favorable risk prostate cancer
    Laurence Klotz
    Division of Urology, University of Toronto, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Urol Oncol 24:46-50. 2006
  2. doi request reprint Maximal androgen blockade for advanced prostate cancer
    Laurence Klotz
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, ON, Canada
    Best Pract Res Clin Endocrinol Metab 22:331-40. 2008
  3. ncbi request reprint Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Canada
    Nat Clin Pract Urol 2:136-42; quiz 1 p following 149. 2005
  4. ncbi request reprint Active surveillance for prostate cancer: for whom?
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario M4N 3M5 Canada
    J Clin Oncol 23:8165-9. 2005
  5. ncbi request reprint How (not) to communicate new scientific information: a memoir of the famous Brindley lecture
    Laurence Klotz
    Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    BJU Int 96:956-7. 2005
  6. ncbi request reprint A re-assessment of the role of combined androgen blockade for advanced prostate cancer
    L Klotz
    Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Canada
    BJU Int 93:1177-82. 2004
  7. ncbi request reprint Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario, Canada M4N 3M5
    Eur Urol 47:16-21. 2005
  8. ncbi request reprint Combined androgen blockade: the case for bicalutamide
    Laurence Klotz
    Sunnybrook and Women s College Health Sciences Centre University of Toronto, Canada
    Clin Prostate Cancer 3:215-9. 2005
  9. ncbi request reprint Cavernosal nerve mapping: current data and applications
    L Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    BJU Int 93:9-13. 2004
  10. ncbi request reprint Combined androgen blockade: an update
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada
    Urol Clin North Am 33:161-6, v-vi. 2006

Detail Information

Publications68

  1. ncbi request reprint Active surveillance with selective delayed intervention for favorable risk prostate cancer
    Laurence Klotz
    Division of Urology, University of Toronto, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Urol Oncol 24:46-50. 2006
    ....
  2. doi request reprint Maximal androgen blockade for advanced prostate cancer
    Laurence Klotz
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, ON, Canada
    Best Pract Res Clin Endocrinol Metab 22:331-40. 2008
    ..In prostate cancer patients at high risk for mortality (based on extent of disease or prostate-specific antigen kinetics), combination therapy with bicalutamide should be considered in preference to monotherapy...
  3. ncbi request reprint Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Canada
    Nat Clin Pract Urol 2:136-42; quiz 1 p following 149. 2005
    ..The results at 8 years were favorable. Longer follow-up will be required if the study is to confirm the safety of this approach in men with a long life expectancy (> 15 years)...
  4. ncbi request reprint Active surveillance for prostate cancer: for whom?
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario M4N 3M5 Canada
    J Clin Oncol 23:8165-9. 2005
    ....
  5. ncbi request reprint How (not) to communicate new scientific information: a memoir of the famous Brindley lecture
    Laurence Klotz
    Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    BJU Int 96:956-7. 2005
  6. ncbi request reprint A re-assessment of the role of combined androgen blockade for advanced prostate cancer
    L Klotz
    Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Canada
    BJU Int 93:1177-82. 2004
  7. ncbi request reprint Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario, Canada M4N 3M5
    Eur Urol 47:16-21. 2005
    ....
  8. ncbi request reprint Combined androgen blockade: the case for bicalutamide
    Laurence Klotz
    Sunnybrook and Women s College Health Sciences Centre University of Toronto, Canada
    Clin Prostate Cancer 3:215-9. 2005
    ..An analysis combining historic trial data suggests that bicalutamide 50 mg in addition to androgen deprivation may reduce the hazard ratio (HR) for prostate cancer mortality by 20% (HR, 0.80; 95% CI, 0.66-0.98)...
  9. ncbi request reprint Cavernosal nerve mapping: current data and applications
    L Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    BJU Int 93:9-13. 2004
    ..These approaches warrant further evaluation...
  10. ncbi request reprint Combined androgen blockade: an update
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada
    Urol Clin North Am 33:161-6, v-vi. 2006
    ..This treatment must be balanced against the potential for an increase in side-effects and a consequent adverse effect on the patient's quality of life...
  11. ncbi request reprint PSA doubling time of prostate carcinoma managed with watchful observation alone
    R Choo
    Toronto Sunnybrook Regional Cancer Center, University of Toronto, Toronto, Ontario, Canada
    Int J Radiat Oncol Biol Phys 50:615-20. 2001
    ..To study prostate-specific antigen (PSA) doubling time of untreated, favorable grade, prostate carcinoma...
  12. ncbi request reprint Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer
    R Choo
    Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Can J Urol 11:2118-24. 2004
    ..To examine the change of histologic grade of untreated, low to intermediate grade, clinically localized prostate cancer over time on repeat prostate biopsy...
  13. ncbi request reprint The role of serial transrectal ultrasonography in a 'watchful waiting' protocol for men with localized prostate cancer
    G Hruby
    Toronto-Sunnybrook Regional Cancer Centre, University of Toronto, Ontario, Canada
    BJU Int 87:643-7. 2001
    ..CONCLUSION: The use of serial TRUS in men with known but untreated prostate cancer is of limited value as a determinant of disease progression...
  14. ncbi request reprint Is there a progression of histologic grade from radical prostatectomy to local recurrence in patients with clinically isolated local recurrence following surgery?
    R Choo
    Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Can J Urol 10:1981-5. 2003
    ..To evaluate whether there is any histologic progression from radical prostatectomy (RP) to local recurrence in patients with clinically isolated local recurrence following RP...
  15. ncbi request reprint Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?
    B K Yap
    Toronto Sunnybrook Regional Cancer Centre, Ontario, Canada
    BJU Int 91:613-7. 2003
    ..To assess the predictive value of serial bone scans as a surveillance tool for bone metastasis in men with clinically localized prostate cancer and managed with watchful observation...
  16. ncbi request reprint Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer
    R Vieth
    Mount Sinai Hospital, Toronto Sunnybrook Regional Cancer Center, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Canada
    Am J Ther 13:394-9. 2006
    ..The therapeutic implication is that vitamin D supplementation in the range of 2000 IU/d, a dose comparable to the effect of summer, can benefit men monitored for rising PSA...
  17. ncbi request reprint Neoadjuvant hormone therapy: the Canadian trials
    L Klotz
    Sunnybrook Health Science Center, University of Toronto, Toronto, Ontario, Canada
    Mol Urol 4:233-7;discussion 239. 2000
    ..Data regarding time to biochemical and clinical progression and overall and disease-specific survival will be required to determine whether this change in the pathologic findings translates into a patient benefit...
  18. ncbi request reprint Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?
    Scott Bagnall
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Semin Oncol 30:587-95. 2003
    ..The outcome of a strategy of selective intervention in good-risk patients based on prostate-specific antigen (PSA) doubling time is summarized...
  19. ncbi request reprint Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience
    Antonio Hurtado-Coll
    Division of Urology, Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Urology 60:45-51; discussion 51. 2002
    ..In this article, we will review the Canadian experience, from the laboratory to the clinic...
  20. ncbi request reprint Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?
    Laurence Klotz
    Division of Urology, University of Toronto, and Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Curr Urol Rep 8:341-4. 2007
  21. ncbi request reprint Intermittent androgen suppression in prostate cancer: the Canadian experience
    Antonio Hurtado-Coll
    Division of Urology, Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Urology 60:52-6; discussion 56. 2002
    ..Intermittent therapy offers quality-of-life benefits during the off-therapy period, as well as reduced cost of treatment. This article will review the >15 years of Canadian experience with intermittent androgen suppression...
  22. doi request reprint Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics
    Yonah Krakowsky
    Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 184:131-5. 2010
    ..This is a detailed report of 5 of 453 patients on surveillance who died of prostate cancer...
  23. ncbi request reprint The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer
    L Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Prostate Cancer Prostatic Dis 8:179-83. 2005
    ..To determine whether the duration of the off-treatment interval in patients being treated with intermittent androgen deprivation therapy can be predicted by the length of the CAG trinucleotide repeat polymorphism in the androgen receptor...
  24. ncbi request reprint Modeling prostate specific antigen kinetics in patients on active surveillance
    Liying Zhang
    Division of Clinical Trials and Epidemiology, and Department of Radiation Oncology, and Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 176:1392-7; discussion 1397-8. 2006
    ..Prostate specific antigen doubling time was used to stratify patients into groups at low and high risk for progression. The prostate specific antigen kinetics in these 2 groups were modeled...
  25. ncbi request reprint Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation
    Peter S Bunting
    Department of Clinical Pathology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Clin Biochem 35:471-5. 2002
    ..To determine the intraindividual variation of prostate-specific antigen (PSA) isoforms in prostate cancer patients managed conservatively with watchful observation...
  26. ncbi request reprint Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention
    Laurence Klotz
    University of Toronto, Canada
    Nat Clin Pract Urol 5:2-3. 2008
  27. ncbi request reprint Active surveillance for favorable risk prostate cancer: rationale, risks, and results
    Laurence Klotz
    University of Toronto Division of Urology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Urol Oncol 25:505-9. 2007
    ..The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed...
  28. doi request reprint Active surveillance for prostate cancer: a review
    Laurence Klotz
    Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, MG408, Toronto, ON, M4N 3M5, Canada
    Curr Urol Rep 11:165-71. 2010
    ..The rationale, patient selection, method of follow-up, triggers for intervention, and recent results of this approach will be reviewed...
  29. ncbi request reprint Expectant management with selective delayed intervention for favorable risk prostate cancer
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario M4N 3M5, Canada
    Urol Oncol 7:175-9. 2002
    ..In these patients, a policy of close monitoring with selective intervention for the 15-20% who progress rapidly is appealing. This approach is currently the focus of several clinical trials...
  30. ncbi request reprint Intraoperative cavernous nerve stimulation during nerve sparing radical prostatectomy: how and when?
    L Klotz
    Sunnybrook Health Science Center, University of Toronto, Ontario, Canada
    Curr Opin Urol 10:239-43. 2000
    ..These approaches warrant further evaluation...
  31. doi request reprint Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer
    N Lawrentschuk
    Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Urol 185:862-8. 2011
    ..We review outcomes in men undergoing salvage radical prostatectomy after failed whole gland high intensity focused ultrasound...
  32. ncbi request reprint Active surveillance for favorable-risk prostate cancer: who, how and why?
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue MG408, Toronto, ON M4N 3M5, Canada
    Nat Clin Pract Oncol 4:692-8. 2007
    ..The results of active surveillance, the criteria for patient selection and the appropriate thresholds for intervention are reviewed in this article...
  33. ncbi request reprint Point: active surveillance for favorable risk prostate cancer
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue MG408, Toronto, Ontario, Canada
    J Natl Compr Canc Netw 5:693-8. 2007
    ..This article reviews the results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention...
  34. ncbi request reprint Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 109:858-67. 2007
    ..Biochemical results from a prospective Phase II trial of intermittent androgen suppression for recurrent prostate cancer after radiotherapy were analyzed for correlations to the onset of hormone-refractory disease...
  35. ncbi request reprint Active surveillance versus radical treatment for favorable-risk localized prostate cancer
    Laurence Klotz
    Sunnybrook Health Sciences Center, University of Toronto, 2975 Bayview Avenue, MG408, Toronto, Ontario M4N 3M5, Canada
    Curr Treat Options Oncol 7:355-62. 2006
    ....
  36. ncbi request reprint Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 107:389-95. 2006
    ..This prospective Phase II study was undertaken to evaluate intermittent androgen suppression as a form of therapy in men with localized prostate cancer who failed after they received external beam irradiation...
  37. ncbi request reprint Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression
    Richard Choo
    Toronto Sunnybrook Regional Cancer Center and Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 167:1664-9. 2002
    ..We assessed the feasibility of a watchful waiting protocol with selective delayed intervention using clinical, prostate specific antigen (PSA) or histological progression as treatment indications for clinically localized prostate cancer...
  38. ncbi request reprint Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
    Richard Choo
    Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Int J Radiat Oncol Biol Phys 52:674-80. 2002
    ..To evaluate the efficacy of postoperative adjuvant radiotherapy (RT) for positive resection margin and/or pathologic T3 (pT3) adenocarcinoma of the prostate with undetectable postoperative prostate-specific antigen (PSA) levels...
  39. ncbi request reprint Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College, Health Sciences Centre, Toronto, ON, Canada
    Clin Prostate Cancer 2:106-10. 2003
    ....
  40. ncbi request reprint Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma
    Richard Choo
    Toronto Sunnybrook Regional Cancer Center, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    BJU Int 94:295-8. 2004
    ..To assess the prostate specific antigen (PSA) doubling time of untreated, clinically localized, low-to-intermediate grade prostate carcinoma...
  41. doi request reprint Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance
    Andrew Loblaw
    Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 184:1942-6. 2010
    ..We determined the proportion of men with nonprogressive prostate cancer on active surveillance who had a trigger for treatment using various measures of prostate specific antigen kinetics...
  42. ncbi request reprint Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer
    Laurence Klotz
    Department of Surgery, University of Toronto, Ontario, Canada
    J Urol 172:S48-50; discussion S50-1. 2004
    ..The challenge is to identify those patients who are not likely to experience significant progression, while offering radical therapy to those who are at risk...
  43. ncbi request reprint Permanent flank bulge is a consequence of flank incision for radical nephrectomy in one half of patients
    S Chatterjee
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Urol Oncol 22:36-9. 2004
    ..This may be particularly relevant in the choice between open partial nephrectomy and laparoscopic radical nephrectomy in a patient with a normal contralateral kidney...
  44. ncbi request reprint The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer
    V Do
    Dept of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    BJU Int 89:703-9. 2002
    ....
  45. doi request reprint A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies
    Stephane Supiot
    Princess Margaret Hospital University Health Network, Toronto, Ont, Canada
    Radiother Oncol 88:53-60. 2008
    ..In a phase I trial, we investigated the feasibility of pre-operative radiotherapy for this patient subset...
  46. doi request reprint Active surveillance for prostate cancer: trials and tribulations
    Laurence Klotz
    Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, MG 408, Toronto, ON, M4N 3M5, Canada
    World J Urol 26:437-42. 2008
    ....
  47. doi request reprint Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
    Laurence Klotz
    Department of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, MG408, Toronto, Ontario M4N 3M5 Canada
    J Clin Oncol 28:126-31. 2010
    ..Other-cause mortality accounted for almost all of the deaths. Additional studies are warranted to improve the identification of patients who harbor more aggressive disease despite favorable clinical parameters at diagnosis...
  48. doi request reprint Degarelix acetate for the treatment of prostate cancer
    Laurence Klotz
    Division of Urology, University of Toronto, Toronto, Ontario, Canada
    Drugs Today (Barc) 45:725-30. 2009
    ..Degarelix is currently available as a 1-month subcutaneous injection and has been approved for the treatment of advanced prostate cancer...
  49. ncbi request reprint Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?
    Laurence Klotz
    Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Semin Radiat Oncol 18:2-6. 2008
    ..The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed...
  50. ncbi request reprint Variation in patterns of practice in diagnosing screen-detected prostate cancer
    Robert K Nam
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Canada
    BJU Int 94:1239-44. 2004
    ....
  51. doi request reprint The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
    Laurence Klotz
    Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, ON, Canada
    BJU Int 102:1531-8. 2008
    ....
  52. ncbi request reprint Cardiovascular effects of androgen depletion and replacement therapy
    Jehonathan H Pinthus
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Urology 67:1126-32. 2006
  53. ncbi request reprint Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases
    Neil Fleshner
    Department of Urology Surgery, Toronto Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Urology 60:93-7. 2002
    ..Clinicians are commonly faced with the dilemma of elevating PSA levels despite negative prostate biopsy results in patients without symptoms of prostatitis...
  54. doi request reprint Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells
    Ahmed Q Haddad
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Nutr Cancer 62:668-81. 2010
    ..Other functional categories altered included chromosome organization, apoptosis, and stress response. These results demonstrate the multiple mechanisms of antitumor activity of DHC and fisetin in prostate cancer cells in vitro...
  55. doi request reprint Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet
    Min Hou
    Division of Urology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada
    Biochem Biophys Res Commun 397:537-42. 2010
    ..These effects may explain its translational role relating to its anti-neoplastic potential...
  56. ncbi request reprint Dietary fat and prostate cancer
    Neil Fleshner
    Division of Urology and Department of Surgical Oncology, Princess Margaret Hospital, University of Toronto, Canada
    J Urol 171:S19-24. 2004
    ..We provide a critical appraisal of the existing evidence for an association between dietary fat consumption and prostate cancer, and review the biologically plausible relationships...
  57. ncbi request reprint Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors
    Ryan Groll
    Department of Surgery Urology, Toronto Sunnybrook Regional Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    Urology 59:551-4. 2002
    ..To determine the clinical value of assessing primary Gleason scoring among patients with grade 7 tumors at needle biopsy with emphasis on its correlation with final pathologic stage and grade...
  58. doi request reprint What is the best approach for screen-detected low volume cancers?--The case for observation
    Laurence Klotz
    Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Urol Oncol 26:495-9. 2008
    ....
  59. ncbi request reprint Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men
    David J A Jenkins
    Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, 61 Queen St East, Toronto, Ontario, Canada M5C 2T2
    J Urol 169:507-11. 2003
    ..Soy proteins used to lower serum cholesterol are rich sources of phytoestrogens. Therefore, we assessed the effect of soy consumption on serum PSA in men who had participated in cholesterol lowering studies...
  60. ncbi request reprint A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma
    Hendrik VAN Poppel
    Department of Urology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Eur Urol 51:1606-15. 2007
    ....
  61. ncbi request reprint [Reevaluation of MAB therapy and progress of endocrine therapy]
    Laurence Klotz
    Gan To Kagaku Ryoho 32:705-28. 2005
  62. ncbi request reprint Critical evaluation of hormonal therapy for carcinoma of the prostate
    Gerald W Chodak
    Midwest Prostate and Urology Health Center, Chicago, Illinois 60640, USA
    Urology 60:201-8. 2002
  63. ncbi request reprint Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
    Urology 60:1-6. 2002
  64. ncbi request reprint Urothelial carcinoma of the prostate
    Juan Palou
    Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain
    Urology 69:50-61. 2007
    ..Prospective and multicenter trials are needed to identify the real incidence and the best management of these patients. In invasive disease of the prostate, the only large series were designed to investigate invasive bladder cancer...
  65. doi request reprint Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer
    Nicholas Bruchovsky
    The Prostate Centre at Vancouver General Hospital, Department of Urologic Sciences, University of British Columbia, Canada
    Clin Genitourin Cancer 6:46-52. 2008
    ..Observations of quality of life (QOL), morbidity, and mortality were obtained from the results of a prospective phase II study of intermittent androgen suppression for recurrent prostate cancer after radiation therapy...
  66. doi request reprint Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer
    Kim N Chi
    Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro Oncology Group, Vancouver, British Columbia, Canada
    J Urol 180:565-70; discussion 570. 2008
    ..We assessed pathological outcomes as well as the feasibility of combined docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing prostatectomy...
  67. ncbi request reprint Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 172:S3-5. 2004
  68. ncbi request reprint Outcomes of treatment vs observation of localized prostate cancer in elderly men
    Mark C Scholz
    JAMA 297:1651-2; author reply 1652-3. 2007